Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 11/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045383 | 1.00 | HRH3 (0.43) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4043156 | 0.86 | RPS6KA2 (0.44) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4043148 | 0.86 | RPS6KA2 (0.44) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4043539 | 0.84 | RPS6KA2 (0.43) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4043536 | 0.84 | RPS6KA2 (0.43) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4039267 | 0.84 | RPS6KA2 (0.43) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4044641 | 0.84 | RPS6KA3 (0.45) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4044650 | 0.84 | RPS6KA3 (0.45) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4039272 | 0.84 | RPS6KA2 (0.43) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 | |
| SCHEMBL4043503 | 0.83 | HRH3 (0.44) | HRH3RPS6KA2RPS6KA3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | HRH3 2039/4885RPS6KA2 3410/4885RPS6KA3 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.